
Marco Poeta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5991624/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lacticaseibacillus rhamnosus GG Counteracts Rotavirus-Induced Ion Secretion and Enterocyte Damage by Inhibiting Oxidative Stress and Apoptosis Through Specific Effects of Living and Postbiotic Preparations. Frontiers in Cellular and Infection Microbiology, 2022, 12, 854989.	1.8	6
2	No Spread of SARS-CoV-2 From Infected Symptomatic Children to Parents: A Prospective Cohort Study in a Controlled Hospital Setting. Frontiers in Pediatrics, 2021, 9, 720084.	0.9	4
3	Bronchiolitis obliterans. , 2021, , 579-587.		0
4	Risk of SARS-CoV-2 Transmission in Health Care Personnel Working in a Pediatric COVID-19 Unit. Hospital Pediatrics, 2021, 11, e42-e47.	0.6	2
5	Diosmectite inhibits the interaction between SARS-CoV-2 and human enterocytes by trapping viral particles, thereby preventing NF-kappaB activation and CXCL10 secretion. Scientific Reports, 2021, 11, 21725.	1.6	13
6	Factors Associated With Severe Gastrointestinal Diagnoses in Children With SARS-CoV-2 Infection or Multisystem Inflammatory Syndrome. JAMA Network Open, 2021, 4, e2139974.	2.8	24
7	Non-cystic fibrosis bronchiectasis in children and adolescents: Neglected and emerging issues. Pediatrics and Neonatology, 2020, 61, 255-262.	0.3	15
8	ls Quarantine for COVID-19 Pandemic Associated with Psychological Burden in Primary Ciliary Dyskinesia?. International Journal of Environmental Research and Public Health, 2020, 17, 8099.	1.2	11
9	Health-care organization for the management and surveillance of SARS-CoV-2 infection in children during pandemic in Campania region, Italy. Italian Journal of Pediatrics, 2020, 46, 170.	1.0	10
10	Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells. Cells, 2020, 9, 2090.	1.8	44
11	Azithromycin for primary ciliary dyskinesia: a milestone. Lancet Respiratory Medicine,the, 2020, 8, 429-430.	5.2	2
12	Effects of pidotimod and bifidobacteria mixture on clinical symptoms and urinary metabolomic profile of children with recurrent respiratory infections: a randomized placebo-controlled trial. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101818.	1.1	15
13	Congenital Lung Malformations: Unresolved Issues and Unanswered Questions. Frontiers in Pediatrics, 2019, 7, 239.	0.9	49
14	Waist Circumference and Healthy Lifestyle Preferences/Knowledge Monitoring in a Preschool Obesity Prevention Program. Nutrients, 2019, 11, 2139.	1.7	7
15	Randomization of Left-Right Asymmetry and Congenital Heart Defects. Circulation Genomic and Precision Medicine, 2019, 12, .	1.6	25
16	Relations of gut liver axis components and gut microbiota in obese children with fatty liver: A pilot study. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 387-390.	0.7	11
17	Three unreported cases of TMEM199-CDG, a rare genetic liver disease with abnormal glycosylation. Orphanet Journal of Rare Diseases, 2018, 13, 4.	1.2	17
18	New Drugs for Pediatric Asthma. Frontiers in Pediatrics, 2018, 6, 432.	0.9	10

Marco Poeta

#	Article	IF	CITATIONS
19	"Changes in Food Selectivity": Evolution towards Self-Induced Vomiting in a Boy with Autism Spectrum Disorder. Journal of Communication Disorders Deaf Studies & Hearing Aids, 2018, 06, .	0.2	0
20	Mediterranean diet to prevent/treat nonalcoholic fatty liver disease in children: A promising approach. Nutrition, 2017, 43-44, 98-99.	1.1	4
21	Three patients with glycosylation deficiencies, chronically elevated transaminases, and low serum ceruloplasmin and copper, caused by mutations in the gene encoding the transmembrane protein TMEM199. Digestive and Liver Disease, 2017, 49, e249.	0.4	0
22	Physical activity rather than food knowledge/preferences underlie waist circumference improvements in early preventive programs. Digestive and Liver Disease, 2017, 49, e284.	0.4	0
23	Multiple gut–liver axis abnormalities in children with obesity with and without hepatic involvement. Pediatric Obesity, 2017, 12, 446-452.	1.4	39
24	Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children, 2017, 4, 66.	0.6	85
25	Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World Journal of Gastroenterology, 2016, 22, 8078.	1.4	148
26	Early onset transient liver disease and rare allelic variants alpha-1 antitrypsin deficiency (A1ATD) Plowell and Mheerlen. Digestive and Liver Disease, 2016, 48, e254.	0.4	1
27	Gut microbiota composition and products contribute to gut–liver axis dysfunction in pediatric obesity related NAFLD, with distinct metabolomic signature. Digestive and Liver Disease, 2016, 48, e260.	0.4	0
28	Emerging Pathomechanisms Involved in Obesity. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 113-119.	0.9	19
29	Efficacy of a multi-compartmental obesity prevention program (the 3P Project) in South Italy preschoolers. Digestive and Liver Disease, 2015, 47, e245.	0.4	0
30	Gut microbiota (GM) and gut-liver axis (GLA) components in obesity related NAFLD: A pediatric pilot study. Digestive and Liver Disease, 2015, 47, e253.	0.4	3
31	Gut-liver axis studies in obese children with and without hepatic complications. Digestive and Liver Disease, 2015, 47, e253.	0.4	1
32	Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 15518.	1.4	162
33	Probiotics to Treat Visceral Obesity and Related Liver Disease. , 2014, , 363-380.		1
34	Novel mechanisms underlying the pediatric obesity epidemics: A pilot study. Digestive and Liver Disease, 2014, 46, e99.	0.4	0
35	Poor adherence to Mediterranean diet in overweight/obese preschoolers: Need for an universal early alimentary prevention. Digestive and Liver Disease, 2014, 46, e98.	0.4	0
36	Identification of malnutrition in children with severe neuromotor disabilities: A still overlooked aspect in our country. Digestive and Liver Disease, 2014, 46, e99.	0.4	0

#	Article	IF	CITATIONS
37	Pediatric non alcoholic fatty liver disease: more on novel treatment targets. BMC Pediatrics, 2013, 13, 109.	0.7	5